Genelex Receives Innovative Technology Designation from Vizient, Inc. for YouScript® Software
Genelex receives Innovative Technology Designation from Vizient, Inc. for YouScript® software that reduces ER visits & hospitalizations with improved, gene-based medication management. Designation recognizes the development of new solutions that benefit the health care industry.
Seattle, WA, January 30, 2016 --(PR.com)-- Genelex announced its YouScript® Precision Prescribing analytics software has received Innovative Technology designation from Vizient, Inc., formerly Novation, the largest member-owned health care company in the country. The designation was based on reviews of YouScript by hospital experts who attended Vizient’s Innovative Technology Expo in November. The annual event provides medical technology suppliers the opportunity to demonstrate their product and gain direct feedback from onsite clinical experts and health care providers on the impact their products may have on improving clinical care and safety, or how it may benefit an organization’s care and business model.
At the intersection of population health and clinical decision support, YouScript answers three key questions – which patients are at the highest risk of adverse drug events, which ones would benefit from genetic testing, and what clinicians should do to optimize the safety and effectiveness of medications. YouScript® Precision Prescribing analytics software is the most advanced and innovative drug interaction software available, integrating pharmacogenetic testing with comprehensive drug-gene and drug-drug interaction information to assess the cumulative impact of a patient’s genetics and drug regimen, and their risk for adverse drug events. Informative, color-coded alerts, and recommended medication alternatives are presented in an easy-to-understand, clinically-actionable format. With YouScript, healthcare providers can reduce trial-and-error prescribing, reduce expenditures, and improve patient outcomes. A recent study published in the Journal of Medical Economics shows that the YouScript® Precision Prescribing System reduces hospitalizations by 39-percent and ER visits by 71-percent in elderly patients taking multiple medications in just 4-months.
Genelex CEO, Kristine Ashcraft stated, “We are honored that Vizient and their hospital experts recognize that YouScript® is a step forward from existing drug interaction tools, and can make medication management, especially for patients on complex regimens, safer and easier. Every day, we hear from patients and providers how much of a difference YouScript has made in their lives. On behalf of the employees of Genelex and especially the patients and providers it can help, we thank Vizient for this designation.”
“Vizient is committed to providing the members we serve with leading-edge technologies that deliver new clinical and operational benefits from what is currently available in the market today,” said Debbie Archer, director of procurement and leader of the Innovative Technology program for suppliers. “After reviewing Genelex’s YouScript® Precision Prescribing Analytics software at our annual Innovative Expo, the hospital experts who attended agreed the product offers unique and incremental benefits over other products available on the market today, and recommended it for the Innovative Technology designation.”
Vizient is the new brand identity for the organizations formerly known as VHA Inc, UHC, and Novation. Since 2003, more than 2000 new and innovative products and technologies have been submitted through the Vizient Innovative Technology program. Vizient works with member-led councils and task forces to identify and review potentially innovative products. If it is determined that a product is innovative, a contract may be awarded outside of Vizient’s competitive bid cycle.
To learn more about Vizient’s Innovative Technology program, visit www.novationco.com/expertise/technology.
Press Contact:
Kristine Ashcraft
Genelex
kashcraft@genelex.com
206-826-1957
At the intersection of population health and clinical decision support, YouScript answers three key questions – which patients are at the highest risk of adverse drug events, which ones would benefit from genetic testing, and what clinicians should do to optimize the safety and effectiveness of medications. YouScript® Precision Prescribing analytics software is the most advanced and innovative drug interaction software available, integrating pharmacogenetic testing with comprehensive drug-gene and drug-drug interaction information to assess the cumulative impact of a patient’s genetics and drug regimen, and their risk for adverse drug events. Informative, color-coded alerts, and recommended medication alternatives are presented in an easy-to-understand, clinically-actionable format. With YouScript, healthcare providers can reduce trial-and-error prescribing, reduce expenditures, and improve patient outcomes. A recent study published in the Journal of Medical Economics shows that the YouScript® Precision Prescribing System reduces hospitalizations by 39-percent and ER visits by 71-percent in elderly patients taking multiple medications in just 4-months.
Genelex CEO, Kristine Ashcraft stated, “We are honored that Vizient and their hospital experts recognize that YouScript® is a step forward from existing drug interaction tools, and can make medication management, especially for patients on complex regimens, safer and easier. Every day, we hear from patients and providers how much of a difference YouScript has made in their lives. On behalf of the employees of Genelex and especially the patients and providers it can help, we thank Vizient for this designation.”
“Vizient is committed to providing the members we serve with leading-edge technologies that deliver new clinical and operational benefits from what is currently available in the market today,” said Debbie Archer, director of procurement and leader of the Innovative Technology program for suppliers. “After reviewing Genelex’s YouScript® Precision Prescribing Analytics software at our annual Innovative Expo, the hospital experts who attended agreed the product offers unique and incremental benefits over other products available on the market today, and recommended it for the Innovative Technology designation.”
Vizient is the new brand identity for the organizations formerly known as VHA Inc, UHC, and Novation. Since 2003, more than 2000 new and innovative products and technologies have been submitted through the Vizient Innovative Technology program. Vizient works with member-led councils and task forces to identify and review potentially innovative products. If it is determined that a product is innovative, a contract may be awarded outside of Vizient’s competitive bid cycle.
To learn more about Vizient’s Innovative Technology program, visit www.novationco.com/expertise/technology.
Press Contact:
Kristine Ashcraft
Genelex
kashcraft@genelex.com
206-826-1957
Contact
Genelex Corp
Kristine Ashcraft
(206) 826-1957
http://www.genelex.com
Kristine Ashcraft
(206) 826-1957
http://www.genelex.com
Contact
Categories